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Abstract
A female patient, with normal familial history, developed at the age of 30 months an episode of diarrhoea, vomit-
ing and lethargy which resolved spontaneously. At the age of 3 years, the patient re-iterated vomiting, was sub-
febrile and hypoglycemic, fell into coma, developed seizures and sequels involving right hemi-body. Urinary excre-
tion of hexanoylglycine and suberylglycine was low during this metabolic decompensation. A study of pre- and
post-prandial blood glucose and ketones over a period of 24 hours showed a normal glycaemic cycle but a failure
to form ketones after 12 hours fasting, suggesting a mitochondrial b-oxidation defect. Total blood carnitine was
lowered with unesterified carnitine being half of the lowest control value. A diagnosis of mild MCAD deficiency
(MCADD) was based on rates of 1-
14C-octanoate and 9, 10-
3H-myristate oxidation and of octanoyl-CoA dehydro-
genase being reduced to 25% of control values. Other mitochondrial fatty acid oxidation proteins were functionally
normal. De novo acylcarnitine synthesis in whole blood samples incubated with deuterated palmitate was also typi-
cal of MCADD. Genetic studies showed that the patient was compound heterozygous with a sequence variation in
both of the two ACADM alleles; one had the common c.985A>G mutation and the other had a novel c.145C>G
mutation. This is the first report for the ACADM gene c.145C>G mutation: it is located in exon 3 and causes a
replacement of glutamine to glutamate at position 24 of the mature protein (Q24E). Associated with heterozygos-
ity for c.985A>G mutation, this mutation is responsible for a mild MCADD phenotype along with a clinical story
corroborating the emerging literature view that patients with genotypes representing mild MCADD (high residual
enzyme activity and low urinary levels of glycine conjugates), similar to some of the mild MCADDs detected by
MS/MS newborn screening, may be at risk for disease presentation.
Introduction
Mitochondrial fatty acid oxidation defects (FAOD) are
rare inherited diseases with clinical presentation ranging
from severe outcome to asymptomatic status. Diagnosis
of FAOD requires specific investigations including bio-
chemical and genetic studies. The most common FAOD
is represented by a deficiency in the activity of the
medium-chain acyl-CoA dehydrogenase (MCAD, EC
3.1.2.20) protein, which is coded by the ACADM gene
(chromosome 1p31) [1-4]. First reported in 1976 [5] and
biochemically characterized in 1982 [6], MCAD defi-
ciency (MCADD) has since been extensively described.
Point mutations in the ACADM gene were reported
early [7,8] and many mutations have been documented
subsequently, in part as a result of the large develop-
ment of screening strategies [9-18]. As a general rule,
these mutations lead to either truncated/absent protein
synthesis, or replacement of one amino acid by another
with a consequent drop in the activity of the mutant
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c.985A>G, which causes the replacement of a lysine by
a glutamate at position 329 of the precursor protein
(position 304 of the mature protein) [3,17], being for
this reason also referred to as the K329E (or K304E)
protein variant. Eighty percent of symptomatic MCADD
patients of European origin are homozygous for this
mutation, and a further 18% of symptomatic MCADD
are associated with the c.985A>G mutation in one allele
and a rare mutation in the other allele [1,3,19,20]. Muta-
tions other than c.985A>G may predominate in non-
European populations [21,22].
MCADD is inherited as an autosomal recessive trait
[2,3,23,24]. Like other genetic b-oxidation defects,
MCADD may cause in early childhood life-threatening
events like hypoketotic/hypoglycaemic comas occurring
during the course of catabolic states which disrupt the
body energetic production/expense balance (infectious
episodes, for instance) [2,3,23,24]. In fact, MCADD may
present phenotypically as either a classical (severe) or a
mild form. In mild MCADD, the residual MCAD activ-
ity is intermediate between that observed in classical
MCADD (usually less than a few percent) and their het-
erozygous carriers (around 50%) [25], the classical form
of the disease resulting mainly from homozygosity for
the c.985A>G mutation as mentioned above. The resi-
dual activity of the ACADM gene product and hence its
impact on cell metabolism and patient clinical presenta-
tion depends on a series of factors including protein
misfolding, MCAD tetramer stability, and thermosensi-
tivity of the mutant protein [3,26-28] along with contri-
bution from the overlapping activities of other
mitochondrial acyl-CoA dehydrogenases and efficacy of
L-carnitine-based detoxification. In turn, a toxic “gain-
of-function” pathogenesis has been also proposed for
some MCAD variants [3].
Febrile episodes may negatively impact the disease out-
come, especially when the mutant protein is thermosensi-
tive, which is the case for the most common K304E
protein variant [28]. The patient has then to face concomi-
tantly not only the increased energy demand but also the
sudden lowering of the fatty acid oxidation-derived energy
production secondary to a drop in residual MCAD activ-
ity. This might explain why one quarter of the patients
with classical MCADD do not survive their first life-threa-
tening episode and why this disease is present in the etiol-
ogy list for sudden infant death syndrome [29-31].
Like patients with classical MCADD, patients with
mild MCADD may develop metabolic decompensation
in their early childhood. They may have to cope
throughout life with neurological sequels or other irre-
versible lesions caused by early childhood metabolic
decompensation. These sequels do not necessarily reflect
the MCADD genotype but rather are the consequences
of the life threatening episode before medical interven-
tion. Recent work, however, suggests that the link
between susceptibility to develop metabolic decompen-
sation and MCADD patient genotype is not straightfor-
ward and that this susceptibility is largely dependent on
environmental triggers such as starvation stress, infec-
tion and/or fever [3,18]. We report here on a patient
with mild MCADD having undergone a severe meta-
bolic decompensation and subsequent clinical sequels.
Genetic studies revealed a previously unreported muta-
tion (c.145C<G) in one of the ACADM alleles combined
with the common c.985A>G mutation in the other
allele. Biochemical investigations of the patient are
reported along with clinical data from the same time
and an assessment of the impact of the new mutant
protein variant is discussed.
Materials and methods
Solvents, reagents and internal calibrators for in vitro
biological explorations
Chemical reagents and solvents were HPLC grade and
were obtained from Merck, acetonitrile from JT Baker,
1-butanol and methanol from Prolabo, and stable iso-
topes including [16-
2H3,1 5 -
2H2]-palmitate (substrate),
[16-
2H3]-pamitoylcarnitine, [8-
2H3]-octanoylcarnitine
and [3-
2H3]-propionylcarnitine (internal standards) from
CDN-Isotopes Inc. L-carnitine and other chemicals were
from Sigma (St Louis, MO).
Determinations of body fluid organic acids, acylglycines,
carnitine (total, unesterified and esterified forms) and
acylcarnitines
Trimethylsilyl derivatives of organic acids were quantified
using capillary gas chromatography (GC) coupled to
mass spectrometry (MS), and total and unesterified carni-
tine levels were determined as previously described
[32,33]. Individual acylcarnitines in body fluids were ana-
lyzed by fast atom bombardment (FAB)-MS or MS-MS
of a blood spot on filter paper (Guthrie card) [33-35].
Preparation of lymphocytes and culture of fibroblasts
Mononuclear cells were isolated from 10 mL of blood,
using a Ficoll-Paque procedure. The pellet was sus-
pended in Dulbecco’s phosphate buffered saline with 0.9
mM Ca
2+ and 0.5 mM Mg
2+, pH 7.35 (PBS), in order to
adjust total cell proteins of the cell suspension to 1 ±
0.4 mg/ml for enzymatic determinations.
Skin fibroblasts were cultured as previously described
[36,37].
Fatty acid oxidation rate studies on lymphocytes and
fibroblasts
Tritiated water release experiments [38] were performed
in triplicate, in 24-well microtiter plates. [9, 10(n)-
3H]
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ml) were used as substrates, at a final concentration of
100 μmol/l in PBS.
The capacity to oxidize
14C lapelled substrates was
examined essentially as described previously [36,37].
Measurement of individual enzymes of fatty acid
oxidation
Mitochondrial acyl-CoA dehydrogenases were assayed
by the ETF reduction assay [38]. Other fatty acid oxida-
tion proteins were assayed by well standardized proce-
dures [39,40].
Genetic studies
Preparation of DNA samples of blood origin and PCR,
purification and sequence analysis of exons of the
ACADM gene were performed as described previously
[12].
Procedure relative to de novo synthesis of acylcarnitines
by whole blood samples
De novo synthesis of acylcarnitines by whole blood sam-
ples incubated with deuterated palmitate was monitored
essentially as described in Dessein et al. [34] with the
ESI tandem mass spectrometry performed with either a
Perkin Elmer mass or a Micromass Quattro PremierTM
mass spectrometer.
Case description
First clinical symptoms and biological data
The patient was born normally as a result of a twin
pregnancy, her twin brother being clinically healthy. Her
eldest brother has also been healthy. She had a normal
gestation and familial history.
At the age of 30 months, she was hospitalized for
diarrhea without fever, vomiting and lethargy. Electroen-
cephalogram and brain scanner examinations were nor-
mal. Glycaemia was normal as well as aminoacidogram.
Discrete biological liver cytolysis was noticed with GOT
and GPT increased at 45 and 90 IU/l, respectively
(upper control values at 30 IU/l) along with echographi-
cal signs of mild hepatomegaly. Viral and bacterial serol-
ogy was negative. This episode spontaneously resolved
in a couple of days, and the patient recovered rapidly to
a healthy status and normal life activities.
At the age of 3 years, she re-iterated an episode of
vomiting which was sub-febrile (38.5°C) and followed by
a coma, requiring a new hospitalization. On this occa-
sion, marked hypoglycaemia (0.17 g/L) was documented
and the patient presented with tonic-clonic seizures on
the right side which persisted for 3 days and was treated
by combined phenobarbital and phenytoin. The recovery
of this status epilepticus was progressive. The child
developed, however, sequels including a deficit of the
right hemi-body, delay in the language acquisition, and
electroencephalographic abnormalities in the rear area
of the left hemisphere. The biological analyses revealed
a liver cytolysis (increased blood levels of GPT [96 IU/l]
and GOT [134 IU/l]) without signs of hepatic failure.
A study of pre- and post-prandial blood glucose and
ketones over a period of 24 hours showed normal gly-
caemias but a failure to form ketones after 12 hours
fasting. This prompted a study of mitochondrial fatty
acid oxidation via metabolite analyses in body fluids
samples and biochemical measurements in cultured skin
fibroblasts and lymphocytes. The diagnostic biological/
biochemical investigations were completed by genetic
studies and functional assessment of de novo acylcarni-
tine synthesis by whole blood samples.
Diagnostic biological and biochemical explorations
- Metabolite analyses
The results of metabolite analyses are given in Table 1.
Urinary organic acid profiles obtained during the coma-
tose metabolic crisis showed increased medium-chain
dicarboxylic acids but neither hexanoylglycine nor sub-
erylglycine were detected by routine GC-MS analysis.
3-Hydroxybutyrate was increased in the urine indicating
some ability to form ketoneb o d i e s .T h ep a t i e n tp r e -
sented with hypocarnitinemia affecting both total and
unesterified carnitine levels which were reduced to half
of the control values. This hypocarnitinemia was treated
by oral L-carnitine supplementation (100 mg/kg/day)
maintained throughout life (with a dose limit of 1.5 g/
day). Several other metabolite analyses in blood and
urine were performed when the patient was under
L-carnitine therapy. Under these conditions, blood total
and unesterified carnitine levels were normalized, and
the esterified to unesterified carnitine ratio was at the
upper control limit. Blood acylcarnitine analysis showed
an increase in octanoylcarnitine with a C8/C10 acylcar-
nitine ratio higher than 5 and evocative of a defect in
octanoate oxidation. In the patient urine, C8 acylcarni-
tines represented more than half of the total acylcarni-
tine content in contrast to the normal urine samples in
which, even under carnitine load, the major acylcarni-
tine is acetylcarnitine [33].
- Biochemical determinations
Fatty acid oxidation rates measured on intact lympho-
cytes (Table 2) were within control range for butyrate
and palmitate labeled at carbon 1, whereas octanoate
oxidation was deficient. Using either myristate or palmi-
tate labeled by tritium substitution of carbons 9 and 10
of the fatty acid indicated residual fatty acid oxidation
activities of 11 and 24% of controls, respectively.
Biochemical determinations were also performed on
patient fibroblast preparations (Table 3). Overall fibro-
blast fatty acid oxidation rates investigated with either
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3H]-myristic acid or [9, 10-
3H]-palmitic acid con-
firmed a fatty acid oxidation defect. Other measure-
ments of mitochondrial oxidation performed on intact
fibroblasts indicated that the fatty acid oxidation defect
involved medium-chain fatty acid (octanoate) b-oxida-
tion. This location of the defect was confirmed, using
either octanoyl-CoA or phenylpropionyl-CoA as a sub-
strate, by the reduction of MCAD activity along with
normal VLCAD and SCAD activities. Reduced oxidation
of phenylpropionate by intact fibroblasts (10% of control
values) further confirmed deficient MCAD activity (data
not shown).
Residual MCAD activity studied by the various proce-
dures was between 10 to 28% of control values and
overall fatty acid oxidation rates were lowered to similar
extents. The activities of other enzymes involved in
Table 1 Major metabolite analysis data in patient
Type of analysis Metabolites Patient Controls
(μmol/mmol
creatinine)
(μmol/mmol creatinine)
URINARY ORGANIC
ACIDS
UPON METABOLIC
CRISIS
3-hydroxybutyrate 930 <56
Dicarboxylic acids
Adipic acid 894 <21
Suberic acid 254 <8
Sebacic acid 138 <2
Hexanoylglycine <2 <2
Suberylglycine <2 <2
(μmol/l) (μmol/l)
CARNITINE FRACTIONS
IN BLOOD
Total carnitine 22 (82
c ) 34.6-83.6
Unesterified carnitine 12 (45
c ) 24.3-83.6
Esterified carnitine 10 (37
c ) 4.0-28.3
Esterified/unesterified carnitine ratio 0.83 (0.82
c) 0.11-0.83
(μmol/mmol
creatinine)
(μmol/mmol creatinine)
BLOOD
ACYLCARNITINES
(DRIED BLOOD SPOT)
c
Octanoyl-carnitine 0.90
a <0.3 (n = 42)
C8/C10 acylcarnitine ratio >5.1
b
URINARY ACYLCARNITINES
c
GS/MS analysis of
lactones
(chemical ionization)
Octanoyl-carnitine 63% Acetylcarnitine as the major
acylcarnitine Hexanoyl-carnitine 24%
Acetyl, isobutyryl, butyryl, isovaleryl and 2-methyl butyryl-
carnitine
Traces
Direct analysis of
acylcarnitines by FAB/
MS
Octanoyl-carnitine 55% Acetylcarnitine as the major
acylcarnitine Hexanoyl-carnitine 10%
Nonanoylcarnitine 5%
Acetyl, isobutyryl, butyryl, isovaleryl, decanoyl and 2-
methylbutyrylcarnitine
Traces
Range values for c.985A>G homozygotes are
a 0.5-15.6 (n = 53) and
b 5.6-87 (n = 62).
C Analytic determinations performed in patient under L-carnitine therapy (100 mg/kg/day).
Table 2 Measurement of fatty acid oxidation rates in lymphocytes
Metabolic steps Substrates Patient Control tested in the same run Controls(n = 40)
(nmol/hr.mg protein) (nmol/hr.mg protein) (nmol/hr.mg protein)
Mitochondrial oxidations assayed
- by carbon dioxide production [1-
14C]-butyrate 2.61 6.60 4.20 ± 1.06 [2.52-7.69]
[1-
14C]-octanoate 1.41 4.77 3.53 ± 0.81 [3.53-6.37]
- by carbon dioxide plus water
soluble material production
[1-
14C]-palmitate 5.70 7.39 6.08 ± 1.03 [4.28-8.51]
- by tritiated water formation [9,10-
3H]-myristic acid 1.03 9.27 7.75 ± 1.73 [4.97-11.20]
[9,10-
3H]-palmitic acid 1.75 7.41 6.12 ± 1.28 [4.00-9.20]
Control values are means ± SD, range control values are given below between brackets.
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tases, b-hydroxyacyl-CoA dehydrogenases and b-ketoa-
cyl-CoA thiolases as well as the ketolysis enzyme
succinyl-CoA ketoacid transferase, were in normal range
values. The proteins involved in cellular utilization of
carnitine and its esters, including carnitine palmitoyl-
transferase types I and II and the plasma membrane car-
nitine transporter(s) also exhibited normal activities in
fibroblast preparations (Table 2).
Genetic studies
PCR amplification of all exons of the human ACADM
gene, including part of the flanking intron sequences,
was carried out as previously described [12] using
intron-located primers under standard conditions. The
PCR products were subjected to bi-directional cycle
sequencing using DNA dye terminator sequencing kits
(BigDye, Perkin-Elmer). Patient DNA samples were
found to be heterozygous for the common c.985A>G
mutation in exon 11. Another heterozygous mutation,
consisting of C replacement by G at position 145 of the
cDNA sequence (c.145C>G) in exon 3 was identified.
Sequence analysis of exons 3 and 11 was then per-
formed on DNA samples from parents and siblings.
Ap e d i g r e et r e ef o rt h et w oACADM mutations is
shown in Figure 1.
Table 3 Major biochemical determinations performed on cultured skin fibroblasts from patient
Metabolic steps Substrates Patient Controls
(nmol/hr.mg protein) (nmol/hr.mg protein)
Mitochondrial oxidations assayed
- by carbon dioxide production [1,4-
14C]-succinate
e 3.28 4.08 ± 0.71 (n = 20)
[1-
14C]-butyrate
f 7.37 8.83 ± 1.69 (n = 20)
[1-
14C]-octanoate
g 1.09 6.75 ± 2.08 (n = 20)
- by carbon dioxide plus water soluble material production [1-
14C]-palmitate
h 10.59 10.85 ± 2.60 (n = 20)
- by tritiated water formation [9,10-
3H]-myristic acid
a 0.90
b 5.81 ± 2.27 (n = 76)
[9,10-
3H]-myristic acid
a,
c 1.03 8.04 ± 1.74 (n = 20)
[9,10-
3H]-palmitic acid
d 3.49 9.39 ± 1.70 (n = 20)
Acyl-CoA dehydrogenases
(ETF as an electron acceptor)
(nmol/min.mg
protein)
(nmol/min.mg
protein)
-VLCAD palmitoyl-CoA
i 0.69 1.3 ± 0.5 (n = 55)
-MCAD octanoyl-CoA
j 0.48 1.7 ± 0.5 (n = 55)
-SCAD butyryl-CoA
k 0.71 1.0 ± 0.4 (n = 55)
Enoyl-CoA hydratases crotonyl-CoA (C4) 307 346 ± 112 (n = 63)
2-dodecenoyl-CoA (C12) 81 78 ± 25 (n = 59)
C12/C4 activity ratio 0.26 0.24 ± 0.05 (n = 59)
b-hydroxyacyl-CoA dehydrogenases acetoacetyl-CoA (C4) 116 99.5 ± 32.1 (n = 105)
b-keto-palmitoyl-CoA (C16) 74 81.8 ± 22.8 (n = 102)
C16/C4 activity ratio 0.64 0.86 ± 0.20 (n = 102)
b-ketoacyl-CoA thiolase b-keto-palmitoyl-CoA (C16) 19.8 20.64 ± 7.79 (n = 47)
acetoacetyl-CoA (no K
+) 5.20 6.44 ± 3.46 (n = 60)
acetoacetyl-CoA (with K
+) 13.7 13.40 ± 6.22 (n = 60)
activity ratio AA-CoA with
K
+ on AA-CoA without K
+ 2.64 2.17 ± 0.59 (n = 60)
Succinyl-CoA Ketoacid Transferase succinyl-CoA and acetoacetate 10.4 12.11 ± 3.60 (n = 25)
Carnitine palmitoyltransferase
Type I (outer) palmitoyl-CoA 0.53 0.58 ± 0.26 (n = 12)
Type II (inner) palmitoyl-CoA 20.70 15.37 ± 3.13 (n = 8)
Cell membrane carnitine transport L-carnitine 0.73 10
-3 0.83 10
-3 ± 0.25 10
-3 (n = 8)
Control values are means ± SD.
aPerformed by two laboratories;
bConjointly run with fibroblasts from a patient with classical MCADD (homozygous for c.985A>G mutation) and for whom
measured activity was 0.4 nmol/hr.mg protein;
c,
dConjointly run with control fibroblasts exhibiting rates of 7.36 and 9.60 nmol/hr.mg protein, respectively;
e,
f,
g,
h Concomitantly run with control fibroblasts
exhibiting rates of 3.29, 8.10, 4.12 and 11.01 nmol/hr.mg protein, respectively;
i,
j,
k Conjointly run with control fibroblast preparations having activities of 0.70, 1.36
and 0.48 nmol/hr.mg protein, respectively.
Dessein et al. Orphanet Journal of Rare Diseases 2010, 5:26
http://www.ojrd.com/content/5/1/26
Page 5 of 9De novo syntheses of acylcarnitines from deuterated
palmitate
De novo syntheses of acylcarnitines from deuterated
palmitate were studied in whole blood samples from
the patient and healthy controls. Relative median
[D5]-acylcarnitine production rates generated from
incubation of whole blood samples with [16-
2H3,1 5 -
2H2]-[D5]-palmitate along with C8 on C4 acylcarnitine
production rate ratio are illustrated in Figure 2 for the
patient and a healthy control. Compared with the pro-
file in this healthy control and with median reference
values originating from 59 distinct healthy control sub-
jects, the data from our patient with mild MCADD
appeared to be pathological. Both the profile of
deuterated acylcarnitine produced from stable-labeled
palmitate and the ratio between rates of production of
C8- and C4-acylcarnitines were abnormal, aligning on
profiles in three patients with classical severe MCADD
(Figure 2, bottom panels). This datum is clearly distin-
guishable from profiles in a carrier adult who was het-
erozygous for the c.985A>G MCAD gene mutation
Figure 1 Pedigree diagram showing haplotypes for the ACADM
allele mutations in the patient, siblings and parents.
Figure 2 De novo individual acylcarnitine synthesis by whole blood samples from the mild MCADD patient, a healthy control and a
adult carrier (top panels), and from patients with classical MCADD (bottom panels). De novo acylcarnitine synthesis rates generated from
deuterated palmitate in the presence of added L-carnitine by whole blood samples and derived C8/C4 acylcarnitine production rates have been
determined in patient (compound heterozygous for c.985A>G and c.145C>G ACADM mutations) and a adult healthy volunteer and is compared
to the same exploration performed in a adult carrier for the c.985A>G ACADM mutation (see top panels). The series of bottom panels report
results of these measurements in individual patients with the classical form of MCADD and with proven homozygocy for the c.985A>G ACADM
gene mutation. Formations of individual [D5]-acylcarnitines in whole blood samples are relative median rates expressed as percentages of
median control values (framed profiles). The ratio between the rates of production of the major C8-acylcarnitine and the C4-acylcarnitine is
expressed as relative median units, i.e. as the number of fold (and not the number of percents of) median control values. Values of C8
acylcarnitine production rates in disrupted histograms are given at the top of these histograms, and values for C8/C4 acylcarnitine ratios are
given below each ratio histogram. The 5
th to 95
th percentile range for relative median production rate values is given in back position of each
framed series of acylcarnitine production rates. The 5
th to 95
th percentile range for relative median C8/C4 acylcarnitine ratios is represented by
the small green rectangle present at the basis of each C8/C4 ratio histogram and was exceeded by all MCADD patient values but neither carrier
nor control values.
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was among those reported in previous work [34];
patients 2 and 3 being sister and daughter of the clas-
sical MCADD patient 1 and of the adult carrier,
respectively.
Discussion
Our patient undoubtedly suffered from a deficiency of
MCAD, presenting with a mild phenotype of the disease
as ascertained by relatively high residual activity from
lymphocytes and fibroblasts and by a low urinary excre-
tion of hexanoylglycine and suberylgycine during meta-
bolic decompensation. At the time of this urine analysis,
acylglycines were determined by GC/MS (with a detec-
tion limit of 2 mmol/mol creatine) and could not be dis-
criminated from control values. Better analytical
detections of urinary acylglycines are obtained by GC/
MS-MS or GC-MS stable-isotope dilution analysis (SID)
of methyl esters, with detection limits less than 0.7-1
mmol/mol creatinine, allowing for upper limit of con-
trols a clear cut-off value close to 1.1 mmol/mol [25,41].
Biochemically, our patient resembled the four mild
MCADD patients described by Zschocke et al. [25] who
had a residual MCAD activity (10-20%) of the same
order of magnitude as in our patient. In fact, these four
cases and our patient all show intermediate (between
controls and severe MCADD patients) values for both
enzyme activities and acylcarnitine levels and ratios. The
residual enzyme activity observed in classical MCADD,
caused by homozygosity for c.985A>G, is usually below
1%. Two of the four patients previously described by
Zschocke et al. [25] were homozygous for ACADM gene
mutations (c.734C>T or c.799G>A [exon 9]) distinct
from the c.985A>G mutation; the other two patients
were compound heterozygous for the c.985A>G muta-
tion in one allele and the c.199T>C (exon 3) mutation
in the other ACADM allele. Genotypically, our patient
resembled the latter two patients, with the c.985A>G
mutation (exon 11) in one allele and a mutation in exon
3 (namely, c.145C>G mutation) in the other allele. This
mutation has never been observed in controls. To our
knowledge, this is the first report for the c.145 C>G
mutation in the ACADM gene.
As a general rule, amino acid changes introduced in a
mature protein affect its conformation and this may
impact its final stability and function/activity. This has
been well documented for the MCAD mutant protein
(K304E) resulting from the c.985A>G mutation. The
MCAD protein requires assembly of the monomers in a
tetramer, which represents the active functional form of
MCAD. In the case of monomers resulting from the
wild-type ACADM gene, the MCAD tetramer is stable.
In the case of K304E monomers, the tetramer dissoci-
ates abnormally rapidly [26], giving rise to a reduced
steady-state concentration of the tetrameric form.
Another contributing factor is impairment of intramito-
chondrial processes including altered monomer folding
or management [27]. Several studies indicate that pro-
tein misfolding is the key event in the loss of MCAD
activity from many protein variants, and that overex-
pressing chaperonins may rescue monomers from aggre-
gation and enhance residual MCAD activity (see [3] and
references therein). As a result of protein misfolding,
accelerated temperature-driven unfolding may affect
MCAD protein variants. This abnormal MCAD loss of
function and thermosensitivity first documented for the
K304E variant, has been recently extended to a number
of MCAD variants [18,42], questioning the view that
some of the missense mutations detected by newborn
screening are less life-threatening than those clinically
proven to be disease causing. In this respect, the rela-
tively high residual activity found in our mild MCADD
patient has not prevented the occurrence of a severe
metabolic decompensation which might have been fatal
in the absence of adequate medical management. A
patient with the R28C mutant protein who had a muta-
tion (c.157C>T), also less severe than the c.985A>G
mutation, died unexpectedly in early childhood [43].
Our mild MCADD patient combines MCAD K304E
and Q24E variant monomers. Conformational character-
istics of the MCAD K304E variant have been repeatedly
described in the literature. The amino acid change is
located in the MCAD C terminal a domain which is
involved in helix-helix interactions taking place in tetra-
mer assembly (see [18] and references therein). As a
result, tetramer assembly is compromised: unemployed
monomers aggregate and are subjected to degradation.
Experimental prevention of monomer aggregation by
overexpressed chaperonins has been shown to result in
increased tetramer assembly along with higher residual
activity (see [3] and references therein).
The Q24E variant has not been previously described.
The amino acid change here occurs in the MCAD N-
terminal a domain. Some of the protein variants with
mutations in this protein region may present with nor-
mal or close to normal enzyme activity [3,18]. Mutations
of this portion of the MCAD protein are also shown to
induce moderate alterations in tetramer assembly and to
disrupt thermal stability. This is the case for the Y42 H
mutant protein for which temperature-driven loss of
activity is greater than normal though lower than that of
common K304E mutant protein [42]. De novo synthesis
of acylcarnitines monitored on whole blood samples
from our patient was consistent with MCADD. The
major acylcarnitine produced from deuterated palmitate
was octanoylcarnitine, other medium-chain (hexanoyl-
and decanoyl-) carnitine esters being also generated in
excess. The C8 to C4 acylcarnitine production rate ratio
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Page 7 of 9was 54-fold that of controls. As a whole, profile and
ratio of acyl-carnitine production rates in our mild
MCADD patient resemble those found in patients with
classical MCADD, indicating clearly functional repercus-
sion of the enzyme defect on the disposal of acyl-CoA.
The carnitine added to incubation media appeared to
mobilize acyl-CoAs unmetabolised by b-oxidation and,
by comparing acylcarnitines production rates to control
values, revealed the level(s) at which b-oxidation was
defective. The acylcarnitine production rates and
increased C8/C4 acylcarnitine de novo synthesis ratio of
our mild MCADD patient are clearly different from
those of the adult carrier of the c.985A>G mutation
(figure 2).
The last but not least issue concerns the carnitine sta-
tus of our patient at the time of metabolic decompensa-
tion. The patient was then not receiving L-carnitine
therapy and her systemic carnitine levels were below
normal (Table 1). This chronic hypocarnitinaemia was
concomitant with a low urinary excretion of hexanoyl-
glycine and suberylglycine. Interestingly, no elevation of
urinary suberylglycine was reported in the urine from
one patient with hypocarnitinaemia in the description of
four MCADD asymptomatic siblings (compound hetero-
zygotes for the common c.985A>G and the c.842G>C
ACADM gene mutations) provided by Albers and cow-
orkers [44]. Zschocke and coworkers on the other hand
discussed elevated acylcarnitine and undetectable 5-
hydroxyhexanoic acid and suberylglycine in their four
mild MCADD patients [25]. Patients with genotypes
representing mild MCADD (high residual enzyme activ-
ity and low urinary levels of glycine conjugates) should
get the same advice as patients with classical MCADD
regarding risks associated with catabolic states and car-
nitine deficiency.
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